Rachelle joined Enzyvant as CEO from Alexion Pharmaceuticals, Inc., where she most recently served as Senior Vice President and Global Franchise Head of Complement across therapeutic areas of hematology, nephrology and neurology. She brings broad experience in US and Global commercial leadership, including multiple high-profile product launches in rare diseases. Previously, Ms. Jacques was Vice President of U.S. Hematology Marketing at Shire and Baxalta, and Vice President, Business Operations for the Global Bioscience Business Unit at Baxter International. Rachelle has lived and worked in the US, Belgium and China. She started her career in finance and has a BA in Business Administration with an emphasis in Accounting from Alma College. Rachelle also serves on the board of Corbus Pharmaceuticals.
Alan Kimura, MD, PhD
Chief Medical Officer
Alan has served as Chief Medical Officer of Enzyvant since April of 2018. Prior to Enzyvant, he served as Chief Medical Officer for SutroVax and led clinical and regulatory strategies for rare diseases at Translate Bio. Alan has held senior clinical development, research, and medical affairs roles at Shire, Novartis, Altus, Transkaryotic Therapies, BioChem Pharma, SmithKline Beecham Biologicals, and Wyeth-Lederle Vaccines. Alan received his B.A. in Bacteriology from University of California – Berkeley, his M.A. and Ph.D. in Microbiology from University of California – Davis, and his M.D. from University of Miami School of Medicine.
Chief Commercial Officer
Morgan has more than 25 years of broad commercial leadership experience in the biopharmaceutical industry. Prior to Enzyvant, he served as the Head of U.S. Commercial for Spark Therapeutics and was responsible for the development of commercial strategy and implementation in the U.S. for Spark’s investigational gene therapy programs. Starting in 2007, Morgan spent seven years at Sanofi-Genzyme and held multiple commercial leadership roles in several of the legacy Genzyme franchises, including the Fabry disease business. Morgan started his career at Allergan and Biogen and holds a BS in Business Management from the University of Massachusetts Lowell.
George O. Elston
Chief Financial Officer and Head of Corporate Development
George was named Chief Financial Officer and Head of Corporate Development of Enzyvant in December 2018. He is a veteran biopharmaceutical executive with more than 25 years’ experience leading global business and financial operations for start-up, private and public companies. George joined Enzyvant after having served as President and Chief Executive Officer of 2X Oncology, Inc. He also was previously the Chief Financial Officer of Juniper Pharmaceuticals, Inc. Currently he is a trustee and Audit Committee Chairman for the Deutsche Bank AG – DBX Trust. George earned his B.B.A. in Public Accounting from Pace University and is a Certified Public Accountant.
Tamara Joseph, JD, LLM
Tamara was named General Counsel of Enzyvant in June of 2018. She has served as General Counsel of InVivo Therapeutics, Cubist Pharmaceuticals, Mayne Pharma, and Transkaryotic Therapies. Earlier in her career, Tamara established and led the Biogen Idec legal department’s operations outside the United States, and she began her legal career at the law firms of Morrison & Foerster and Fried Frank. She has a JD from the University of Michigan Law School and LLM degrees from the College of Europe in Belgium and the University of Paris. Tamara is also an independent director at public health non-profit Heluna Health and is a member of that Board’s Executive Committee and Chair of its Governance & Nominating Committee.
Judy Chuk, PhD
VP, Strategy & Operations
Judy is responsible for ensuring operational resources for advancement of Enzyvant’s portfolio and strategic development of the business. Judy is a bench scientist by training and brings over 10 years of strategic planning, business operations, and portfolio management experience across multiple therapeutic areas in the biopharma industry. Her experience spans across many functional areas including all phases of drug discovery, development, and commercialization. Most recently, she served as COO and Head of Strategy and Operations for Pfizer’s Rare Disease Research Unit in Cambridge, MA. Judy holds a PhD from Harvard University and a BA from Rutgers University.
Alex Tracy, PhD
VP, Pharmaceutical Development and Manufacturing
Alex has approximately 20 years of experience in pharmaceutical product development and manufacturing for both biologic and small molecule products across a broad range of dosage forms. Alex began his career at Bayer Biologics, and has held senior positions in product development at KBI Biopharma, Novartis Vaccines, Hospira/Pfizer, and Roivant Sciences. Alex holds a PhD in Biochemistry and Molecular Biology from the University of Georgia, an MS in Chemistry from George Mason University and a BS in Chemistry from the College of William and Mary.